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Abstract
Background: The C-terminal domain (CTD) of HIV-1 capsid (CA), like full-length CA, forms dimers in solution and
CTD dimerization is a major driving force in Gag assembly and maturation. Mutations of the residues at the CTD
dimer interface impair virus assembly and render the virus non-infectious. Therefore, the CTD represents a potential
target for designing anti-HIV-1 drugs.
Results: Due to the pivotal role of the dimer interface, we reasoned that peptides from the a-helical region of the
dimer interface might be effective as decoys to prevent CTD dimer formation. However, these small peptides do
not have any structure in solution and they do not penetrate cells. Therefore, we used the hydrocarbon stapling
technique to stabilize the a-helical structure and confirmed by confocal microscopy that this modification also
made these peptides cell-penetrating. We also confirmed by using isothermal titration calorimetry (ITC),
sedimentation equilibrium and NMR that these peptides indeed disrupt dimer formation. In in vitro assembly
assays, the peptides inhibited mature-like virus particle formation and specifically inhibited HIV-1 production in cell-
based assays. These peptides also showed potent antiviral activity against a large panel of laboratory-adapted and
primary isolates, including viral strains resistant to inhibitors of reverse transcriptase and protease.
Conclusions: These preliminary data serve as the foundation for designing small, stable, a-helical peptides and
small-molecule inhibitors targeted against the CTD dimer interface. The observation that relatively weak CA binders,
such as NYAD-201 and NYAD-202, showed specificity and are able to disrupt the CTD dimer is encouraging for
further exploration of a much broader class of antiviral compounds targeting CA. We cannot exclude the possibility
that the CA-based peptides described here could elicit additional effects on virus replication not directly linked to
their ability to bind CA-CTD.
Background
During HIV-1 assembly and morphogenesis, the struc-
tural protein, Gag, organizes into two completely differ-
ent arrangements, immature and mature forms. In the
immature form, Gag remains intact, whereas in the
mature form, Gag is cleaved by the viral protease (PR).
The formation of this mature particle is essential for
HIV-1 infectivity and the capsid protein (CA) obtained
from the Gag cleavage product plays a central role in
forming the conical virion core that surrounds the viral
genome. The CA protein consists of two domains, the N-
terminal domain (NTD, aa 1-145) and the C-terminal
domain (CTD, aa 151-231). These two domains are con-
nected by a 5-amino-acid linker. The CA-CA contacts in
both immature and mature particles have been modeled
based on X-ray structures of isolated domains and image
reconstructions by cryo-electron microscopy of mature
virions and assembled virus-like particles (VLPs) [1-8].
Recently, a pseudo-atomic model of the full-length HIV-
1 CA hexameric structure was reported, which provided
structural insights on the mechanism of action of some
known assembly inhibitors [5,7,9]. HIV-1 CA plays a cru-
cial role in viral assembly, maturation and also early
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and CTD lead to defects in viral assembly and release
[10-21]. Taken together, it is evident that CA plays an
important role in HIV-1 assembly and maturation, and
has been recognized as a potential target for developing a
new generation of drugs for AIDS therapy [22-27].
The NTD of CA binds to cyclophilin A [28,29] and is
important for viral core formation. However, critical
determinants of Gag oligomerization, essential for viral
assembly, are located in the CTD [30]. In addition, the
CTD encompasses the most conserved segment of Gag
known as the major homology region (MHR). Mutation
of retroviral CA MHRs leads to severe defects in viral
assembly, maturation and infectivity [19,31-37]. The iso-
lated CTD of HIV-1 CA, like full-length CA, forms a
dimer in solution. It has been shown that CTD dimeri-
zation is a major driving force in Gag assembly and
maturation [10,15]. Several structures of the CTD dimer
have been reported, providing critical information on
the dimer interface [38-41]. Mutation of the interface
residues in the CTD monomer disrupts dimer formation
[42], impairs CA assembly and abolishes virus infectivity
[10,15]. The CTD therefore plays an important role in
viral assembly and maturation and is a potential target
for developing a new class of anti-HIV-1 drugs [6,43].
Protein-protein interactions play a key role in a range
of biological processes such as antigen-antibody interac-
tion [44-46], viral assembly, programmed cell death, cell
differentiation and signal transduction. Therefore, con-
trolling these vast arrays of interactions offers opportu-
nities for developing novel therapeutic agents. However,
inhibiting these processes by traditional drug discovery
techniques may be complicated and challenging due to
the shallow binding interfaces and relatively large inter-
facial areas involved in most protein-protein interac-
tions. Until recently, it was believed to be virtually
impossible to inhibit protein-protein interactions to
achieve therapeutic benefit. However, this notion is now
changing due to recent advances in this area [45-50]. In
addition, recent studies on crystallized antigen-antibody
complexes have shown that only a limited number of
residues from each protein partner are involved in med-
iating protein-protein interactions. These restricted
areas at the binding interfaces are known as ‘hot spots’,
which are small areas of bumps and holes that account
for most of the protein interface’s free energy of bind-
ing. Therefore, it has been established that inhibitors do
not have to block the entire binding surface but target-
ing the ‘hot spots’ may be sufficient to inhibit protein-
protein interactions [51,52].
Dimeric proteins provide a classical example of pro-
tein-protein interactions through surface recognition.
There are several examples of competitive inhibitors of
protein dimerization that exploit the structure of protein
interfaces. For example, interfacial peptides have been
shown to inhibit dimerizaton of HIV-1 integrase, pro-
tease and reverse transcriptase [53-56]. However, none
of these peptides is clinically useful due to their lack of
cell permeability. HIV-1 CA forms dimers in solution
with modest affinity (Kd =1 8μM). The dimer interface
has been mapped to CTD helix II by various techniques
that show significant variability in the packing of the
subunit [38,41,57,58]. The solution structure reported by
Byeon et al. [57] indicated considerable differences from
the structure (2BUO) reported by Ternois et al. [58] and
1A8O reported by Gamble et al. [38] but similar to
1A43 and 1BAJ dimer structures reported by Worthy-
lake et al. [41]. Because the CTD dimer plays a critical
role in HIV-1 assembly, we have carefully analyzed the
x-ray structure of the CTD dimer (PDB codes: 1a43)
and selected a short a-helical segment (aa 178 - 192)
from one monomer at the dimer interface region as a
starting point for designing inhibitors. These peptides
may competitively bind to one monomer of the CTD
and prevent CTD dimerization. The biggest challenge
facing the use of these short peptides is that they are
normally unstructured in solution and do not penetrate
cells. Consequently, they cannot be used clinically. We
reasoned that hydrocarbon stapling would stabilize the
helical structure of the short peptides and would make
them cell penetrating as was observed in the case of
NYAD-1-type peptides [59] and shown by others [60].
In addition, short hydrocarbon-stapled peptides have
been shown to be viable substitutes for small-molecule
inhibitors, which can have a larger surface area to bind
to the relatively more flat protein binding surface and
showed great potential as future drugs [60-63]. We
report in this study the rational design of such peptides
(Figure 1), which display anti-HIV-1 activity. The data
obtained in this study may lay the foundation for the
development of small-molecule inhibitors targeted to
the CA dimer interface.
Results
Stapling enhances the a-helicity of dimer interface
peptides
We used circular dichroism spectroscopy to determine
the secondary structure characteristics of the stapled
dimer interface peptide, NYAD-201, its linear derivative
NYAD-209 and a mutant analog of NYAD-201 (NYAD-
233). In NYAD-233, the key residues W184 and M185
in NYAD-201 have been replaced with alanine as
reported [64]. The stapled peptides NYAD-201 and
NYAD-233 showed typical a-helical spectra with
minima at 208 and 222 nm. In contrast, the linear pep-
tide NYAD-209 showed two minima, at 200 and 218
nm (Figure 2), suggesting that the secondary structure
of the linear peptide adopts neither a random structure
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the linear peptide was recently reported [65].
Stapled peptides penetrate cells
To show that the stapled peptides NYAD-201 and
NYAD-233 penetrate cells, we examined cellular
uptake of FITC-conjugated NYAD-201 and NYAD-233
by confocal microscopy. We also used the FITC-conju-
gated linear peptide NYAD-209 as a control. The data
(Figure 3) demonstrate that the linear peptide does not
penetrate 293T cells whereas the stapled peptides
NYAD-201 and NYAD-233 (Additional file 1, Figure
S1) penetrate cells.
Stapled peptides enhance dissociation of dimers
The effect of dimer interface peptides on the dissocia-
tion of CA CTD was investigated by two independent
biophysical techniques, isothermal titration calorimetry
and analytical centrifugation.
The effect of the dimer interface peptide, NYAD-203,
a soluble analog of NYAD-201, on dimer dissociation
was first examined by isothermal titration calorimetry
(ITC). Dilution of CTD by sequential ITC injections
into buffer, pH 7.3, 30°;C gave a series of endothermic
heat pulses (Figure 4) consistent with dissociation of
protein oligomers modeled as dimers, with dimer disso-
ciation constant (Kdiss)~ 1 5μM and dissociation
enthalpy (ΔHdiss)o f1 0 . 7k c a lm o l e
-1. Similar results
were obtained in the presence of stapled peptide, but
with progressively increased Kdiss with increasing pep-
tide concentration (Table 1). ITC of an unstapled con-
trol peptide (NYAD-401; Seq: IRQGPKEPFRDYVDR)
showed no apparent heat effect, supporting the conclu-
sion that binding is significant only for stapled peptides
under these conditions. These results are qualitatively
consistent with the hypothesis that stapled peptides bind
competitively to the CTD monomer and inhibit dimeri-
zation. For such a mechanism, the apparent dimer dis-
sociation constant should depend on the free peptide
(inhibitor) concentration ([I]) and binding affinity (KI)a s
follows:
Kdiss =K diss,0(1 + [I]/KI)2
Figure 1 Sequences and primary structure of linear and
hydrocarbon-stapled peptides, indicating the stapling sites.
Figure 2 Circular dichroism (CD) spectroscopy study of NYAD-
201, its linear analog NYAD-209 and a double mutant (W184A
and M185A) of NYAD-201 (NYAD-233) to determine their
secondary structure. NYAD-201 and NYAD-233 showed
characteristic minima at 208 and 222 nm indicating its a-helical
structure whereas the linear analog displayed no minima in those
regions.
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inhibitor concentrations:
Kdiss ∼ = Kdiss,0(1+C I/KI)2
where Ci is the total peptide inhibitor concentration in
the mixture. This analysis is, however, further compli-
cated by apparent self-association of the peptide (see
NMR section) that reduces the availability of free mono-
mer (lower [I]) at higher concentrations and thus leads
to underestimation of peptide binding affinities and a
concentration dependence of apparent Ki.H o w e v e r ,b y
use of the above equations and extrapolation to low
concentrations, we obtain a value of Ki =4 0( ± 5 )μM
for the binding of stapled peptide (NYAD-203) mono-
mer to CTD under these conditions. This value of Ki is
slightly higher, though of comparable order of
magnitude to the self-association dimerization constant
of the CTD, thus validating the primary hypothesis that
the subunit interaction free energy is dominated by this
peptide region.
The impact of NYAD-203 on the dissociation of the
CA dimer was also evaluated by analytical ultracentrifu-
gation. Combined sedimentation velocity and equili-
brium approaches were used to characterize
dimerization of CA.
In the first set of experiments, the CA alone and the
CA with different ratios of NYAD-203 were analyzed by
sedimentation velocity centrifugation. The CA alone (30
μΜ) yielded a single symmetrical peak (data not shown).
CA (30 μΜ) with different ratios of NYAD-203 (CA:
NYAD-203 = 1:1 or 1:3) also yielded a single symmetri-
cal peak (data not shown).
Figure 3 Cell penetration of NYAD-201 and its linear analog NYAD-209 in 293T cells. Confocal microscopy images of 293T cells incubated
for 20 hours at 37°C with FITC-conjugated peptides. Upper panel: Left, Differential Interference Contrast (DIC) image of cells with FITC-b-Ala-
NYAD-209; Center, FITC fluorescent image of the same cells with FITC-b-Ala-NYAD-209; and Right, Overlay of DIC and FITC fluorescent images.
Lower panel: Left, DIC image of cells with FITC-b-Ala-NYAD-201; Center, FITC fluorescent image of the same cells with FITC-b-Ala-NYAD-201; and
Right, Overlay of DIC and FITC fluorescent images. A total of 200 cells were scored in each treatment with FITC-b-Ala-NYAD-209 or FITC-b-Ala-
NYAD-201. The percentage of cells in the population that exhibited the internal staining is shown at the bottom right of the middle panel.
Zhang et al. Retrovirology 2011, 8:28
http://www.retrovirology.com/content/8/1/28
Page 4 of 18In the second set of experiments, the possible effect of
NYAD-203 on dimer stability was analyzed by sedimen-
tation equilibrium. As shown in Figure 5, the apparent
molecular weight for CA in the absence of or in the pre-
sence of different ratios of NYAD-203 was determined.
The CA alone (30 μΜ) yielded an apparent molecular
weight of 41,213 Daltons. CA: NYAD-203 at a 1:1 molar
ratio yielded an apparent molecular weight of 30,343
Daltons and at a 1:3 ratio yielded an apparent molecular
weight of 27,338 Daltons.
Theoretically, the observed decrease in the apparent
molecular weight could be due to the establishment of
rapidly reversible monomer-dimer dissociation equili-
brium. Therefore, the data point to a shift in the asso-
ciation-dissociation equilibrium, indicative of an
increased dissociation to monomer in the presence of
higher doses of NYAD-203.
Mapping interactions between CTD and stapled peptides
At very low CTD concentrations (<10 μM) the protein is
predominantly monomeric (>90%) and upon binding to
the peptide, the structural perturbations induce chemical
shift changes in the aliphatic resonances followed by
1H-
13C HSQC spectra shown in Figure 6. A characteristic fea-
ture of the CTD dimer interface in solution is the overall
variability of Helix II, a source for significant exchange
broadening of resonances from residues located in Helix II
at the dimer interface [66]. Although the selective loss of
NMR signals from Helix II limited the information avail-
able for mapping the exact binding site of the peptide we
observed concentration-dependent chemical shift changes
elsewhere in the hydrophobic core of the protein (Figure
6B). The extent of chemical shift perturbation strongly
suggests a reorganization of the helical core structure of
the CTD upon complex formation with the peptide. In
Figure 6C, the resonances from Leu190 Cδ1/Hδ1a n d
Lys199 Ca/Ha (Additional file 2, Figure S2), are each
represented by two cross-peaks instead of a single peak in
the
1H-
13C HSQC spectra. The differential intensities of
the two peaks are population weighted corresponding to
the free and bound states, respectively. Similar population-
weighted cross-peaks in the ‘slow exchange regime’ of the
NMR time scale were observed through the titration else-
where in the protein. As expected, upon increasing the
peptide concentration to 25 μM the cross-peak intensity
of Leu190 Cδ2 in the bound fraction of CTD increases to
100% (Figure 6A), but surprisingly diminishes at higher
peptide concentrations (Figure 6C). Structural characteri-
zation of the isolated peptide NYAD-203 by NMR
revealed a helical structure for residues 3-14 that self-
associates to form polymeric species (Figure S2). The
four-fold excess of peptide required to saturate 7 μMC T D
yields a binding affinity less than 10 μM. The affinity of
NYAD-203 for monomeric CTD at low concentrations is
apparently higher compared to the value of 40 μM
obtained from the ITC experiments. It is very likely that at
Figure 4 ITC data for sequential dilution of 10 μl aliquots of
CTD (ca. 250 μM) into buffer at 30°;C. Upper panel: raw data
comparing endothermic dilution heat effects in the presence and
absence of peptide (NYAD-203). Lower panel: integrated heats and
theoretical fits for dilution of CTD alone (black square) or in the
presence of 50 (white square), 200 (black circle), or 350 (white circle)
μM peptide inhibitor. The lines are theoretical fits to a dimer
dissociation model using parameters listed in Table 1. Insert:
Concentration dependence of the apparent peptide affinity
constant, KI,App. Linear extrapolation to zero concentration gives an
estimate of KI = 45 (±5) μM for binding of peptide to CTD in the
absence of peptide self-association.
Table 1 Apparent thermodynamic parameters for
dissociation of CTD dimers, as determined by ITC
dilution experiments at 30°;C in the presence of stapled
peptide NYAD-203 with concentration, CI
CI/μMK diss/μM ΔHdiss/kcal mole
-1 200 μM CTD (fm)*
0 15.3 (±3.6) 10.7 (±0.7) 18%
50 31.2 (±6.6) 9.1 (±0.3) 24%
200 33.2 (±3.9) 10.8 (±0.2) 25%
350 40.5 (±6.2) 10.9 (±0.2) 27%
*f m is the estimated fraction of CTD occurring as monomers in solution under
these conditions, calculated from the monomer-dimer equilibrium expressions.
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XL-A/XL-I Analytical ultracentrifugation. The CA concentration was fixed at 30 μM. (A, B & C) The residual difference between the fitted curve
and the experimental data and (A1,B 1 &C 1) Plot of Absorbance at 280 nm vs. centrifugal radius in the absence (control) or presence of 30 μM
and 90 μM of NYAD-203, respectively. The open circles represent the experimental data and the solid lines are the best fit using an ideal single-
species model.
Figure 6 The
1H-
13C HSQC spectra of CTD complexed with the peptide NYAD-203. (A) The methyl region of the free and peptide (25 μM)
complexed [U C
13,N
15] CTD from the
1H-
13C HSQC spectra is shown in the panel. (B) CTD residues perturbed upon binding to the peptide and
could be assigned unambiguously are annotated (bold/black) in the structure. (C) The population weighted changes in the Cδ2 peak intensity of
Leu190 from CTD in the free and bound states at four peptide concentrations.
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experiments self-association dominates and to a degree
competes with the interaction between the peptide and
protein.
NYAD-201 specifically inhibits HIV-1 production
To investigate whether NYAD-201 disrupts HIV-1
assembly in cell culture, we transfected 293T cells with
the full-length HIV-1 molecular clone pNL4-3, and 5 h
after transfection treated with varying concentrations of
NYAD-201 for 18-20 h. Cells were then metabolically
labeled for 2 h with [
35S]Met-Cys, and labeled viral pro-
teins in cell and virion lysates were immunoprecipitated
w i t hH I V - I ga n da n a l y z e db yS D S - P A G Ef o l l o w e db y
fluorography [67]. As shown in Figure 7A, the release
efficiency of HIV-1 was reduced in a concentration-
dependent manner; with 50 μMN Y A D - 2 0 1t h e r ew a sa
3-fold reduction in virus release. As a control, we also
included peptide NYAD-233, in which the key dimer
interface residues “WM” in NYAD-201 were changed to
Ala-Ala (Figure 1). No defect in virus release efficiency
was observed with the NYAD-233 control peptide (Fig-
ure 7A). To examine whether the inhibition of virus
release mediated by NYAD-201 is specific to HIV-1, we
tested the effect of this peptide on the release of another
lentivirus, equine infectious anemia virus (EIAV) in
293T cells. Interestingly, the release of EIAV particles
was not impaired by NYAD-201 (Figure 7B), indicating
that the inhibiting effect of NYAD-201 on HIV-1 parti-
cle production was not the result of non-specific effects
such as cytotoxicity. To address the possibility that the
difference in sensitivity of HIV-1 vs. EIAV to NYAD-
201 was the result of Gag being processed by PR (for
HIV-1 in Figure 7A) or not being processed (for EIAV
in Figure 7B), we tested in parallel a CMV promoter-
driven HIV-1 Gag expression vector. Again, we observed
that HIV-1 VLP production was modestly reduced
whereas EIAV particle production was not affected
(Figure 7B). Together, these results suggest that binding
of NYAD-201 to the CA CTD modestly but specifically
interferes with HIV-1 particle production in cells.
Stapled peptides inhibit mature-like particle formation
To determine whether NYAD-201 disrupts the assembly
of both immature or mature-like particles we set up two
in vitro assembly assays [59]. We used full-length Gag
proteins to form spherical immature-like particles. The
effect of inhibitors on immature particle assembly was
studied by performing assembly reactions in the pre-
sence of varying doses of NYAD-201.
NYAD-201 failed to disrupt immature-like particle
formation even at molar equivalent dose (data not
shown). For the mature-like particles, we obtained tube-
shaped particles from purified CA, [3,68] which when
exposed to NYAD-201, showed a clear dose-response
effect (Figure 8A and 8B). At even a 0.25-fold molar
Figure 7 NYAD-201 inhibits HIV-1 but not EIAV particle production. (A) 293T cells were transfected with pNL4-3 and 5 h after transfection
treated with indicated concentrations of NYAD-201 or NYAD-233 for 18 h. Cells were then metabolically labeled with [
35S]Met/Cys for 2 h. Cells
were lysed and virions were collected by ultracentrifugation. Cell and virus lysates were immunoprecipitated with HIV-Ig and subjected to SDS-
PAGE; protein bands were quantified by phosphorimager analysis. HIV-1 release efficiency was calculated as the amount of virion-associated p24
relative to total (cell + virion) Gag. (B) 293T cells were transfected with CMV-driven vectors expressing EIAV (pPRE-Gag) or HIV-1 (pCMVdeltaR8.2/
PR-) Gag and treated with NYAD-201 at indicated concentrations. After 18 h, peptide-treated cells were metabolically labeled with [
35S]Met/Cys
for 2 h (HIV-1) or 5 h (EIAV) and immunoprecipitated with HIV-Ig or anti-EIAV antiserum. The release efficiency was calculated as the amount of
virion-associated Pr55
Gag to total Pr55
Gag in cells and virions. P values were calculated by Student’s t-test, with P < 0.01 considered significant. N
= 3, ± SD.
Zhang et al. Retrovirology 2011, 8:28
http://www.retrovirology.com/content/8/1/28
Page 7 of 18equivalent of NYAD-201, substantial disruption of tube-
shaped particles was observed. Complete disruption
was attained at molar equivalent and higher doses
(Figure 8A and 8B). NYAD-233, the mutant stapled pep-
tide lacking the key “WM” motif (Figure 1), failed to
d i s r u p tm a t u r e - l i k ep a r t i c l e se v e na t3 - f o l dm o l a r
equivalent dose (Figure 8C). A scrambled hydrocarbon-
stapled peptide, NYAD-215, showed no effect on the
formation of mature-like particles (data not shown). The
rationale behind using CA instead of CANC to form the
mature-like particles was to confirm that NYAD-201
targets CA only [59].
Stapled dimer interface peptides target infectivity at a
post-entry stage
We used human SupT1 cells, incubated with GFP-Vpr-
labeled HIV-1 virions in the presence of NYAD-201 or
the peptide-based HIV-1 fusion inhibitor T-20
Figure 8 Inhibition of in vitro assembly by NYAD-201. (A) Negatively stained EM images of mature-like particles resulting from in vitro
assembly of CA proteins in the presence of no peptide (Control), 0.25-, 0.5-, 1.0-, 3.0- and 5-fold molar equivalent of NYAD-201. (B) A dose-
response effect of NYAD-201 on the tube-like mature particle formation. (C) In vitro assembly of CA proteins in the presence of no peptide
(control) and 3-fold molar equivalent of NYAD-233.
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shown). T-20 is the first clinically used peptide-based
drug designed to inhibit HIV-1 entry [69-72]. Fluores-
cence-activated cell sorting (FACS) analysis demon-
strated that 36%, 41% and 38% of SupT1 cells were GFP
+a t5 0μM, 25 μM or 12.5 μM NYAD-201, respectively,
similar to the levels observed (35%) in the absence of
NYAD-201. In contrast, T-20a t1 1 1n Ms u b s t a n t i a l l y
inhibited viral entry. The ability of T-20 to significantly
reduce the GFP+ signal strongly argues that the signal is
derived from particles that have entered the cell rather
than from those that remain bound to the cell surface.
Since NYAD-201 is a CA-binding peptide and its
interaction with the CTD inhibits viral core formation,
we tested whether NYAD-201 could inhibit virion
infectivity. To this end, we performed single-cycle infec-
tivity assays in the TZM-bl indicator cell line [73,74].
The assays were conducted under several different con-
ditions (Figure 9). Virus-producing cells were incubated
with 12.5, 25 and 50 μMN Y A D - 2 0 1f o rt w oo rf o u r
days and the released virions were collected. RT-normal-
ized virus stocks were used to infect TZM-bl cells. As
shown in Figure 9A, virions produced from cells treated
for four days with NYAD-201 showed a two-fold reduc-
tion in infectivity. We note that peptide from the produ-
cer cell supernatant was diluted ~30-fold in the TZM-bl
infectivity assay (see Figure 9 legend). Furthermore, the
concentration of active peptide in the medium after two
or four days in culture is likely to be considerably lower
than the concentration added initially. We also treated
Figure 9 NYAD-201 inhibits HIV-1 infectivity. (A) Five hours post transfection with pNL4-3, 293T cells were treated with 12.5, 25, and 50 μM
NYAD-201 for 2 or 4 days and supernatant were collected and monitored for RT activity. Approximately 7 μl RT-normalized virus stocks were
used to infect the TZM-bl cells for 2 h in a total volume of 200 μl. This approach led to a dilution of peptide concentration from the producer
cell supernatant of ~30-fold. Two days after infection, cells were washed, lysed and assayed for luciferase activity. (B) Cells or virions were treated
with 5, 20 or 50 μM NYAD-201 before, during, or after infection as described in Methods. Infection of TZM-bl cells was carried out for 2 h and
two days after infection cells were washed, lysed and assayed for luciferase activity. (C) NYAD-201 or NYAD-233 were added to TZM-bl cells at
indicated concentrations during the 2 h infection. Two days after infection cells were washed and luciferase activity was measured as in A. (D)
HIV-1 virions were pseudotyped with VSV-G by cotransfecting the Env-defective pNL4-3 derivative (pNL4-3/KFS) with the VSV-G expression vector
pHCMV-G. RT-normalized WT and VSV-G pseudotyped virions were used to infect TZM-bl cells in the presence of the indicated concentrations of
NYAD-201 for 2 h. Two days after infection, luciferase activity was measured in cell lysates. N = 4 for A, B, D; n = 3 for C; ± SD.
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target cells before or after infection, or treated with pep-
tide during the two-hour infection period. Interestingly,
treating the virions or target cells prior to infection
reduced the infectivity by two- to three-fold; however, if
the peptide was present during the two-hour infection
period the inhibition was more severe (5-6 fold). Treat-
ing cells postinfection imposed a modest (two-fold)
defect in virion infectivity (Figure 9B). As a control for
these infectivity assays, we used the control peptide
NYAD-233 (Figure 1). Again, peptide NYAD-201 inhib-
ited virus infectivity by >5-fold when present during the
two-hour infection period, whereas NYAD-233 had no
effect on particle infectivity (Figure 9C).
These results suggest that in addition to inhibiting vir-
ion assembly and maturation, NYAD-201 may also
affect an entry and/or early post-entry step in the repli-
cation cycle. To investigate this issue in more detail, we
tested whether pseudotyping virions with VSV-G could
bypass the infectivity block. TZM-bl cells were infected
with VSV-G-pseudotyped NL 4 - 3i nt h ep r e s e n c eo f
NYAD-201. Intriguingly, the infectivity of VSV-G-pseu-
dotyped HIV-1 was not inhibited under these conditions
(Figure 9D). This Env-dependent effect suggests that the
infectivity defect imposed by NYAD-201 can be reversed
by altering the virus entry pathway. It is important to
note that there is precedent in the literature for a CA-
dependent defect in core assembly being reversible by
VSV-G pseudotyping [75].
Anti-HIV-1 activity and cytotoxicity of stapled peptides in
cell-based assays
We measured the anti-HIV-1 activity of NYAD-201 and
its analogs (Figure 1) in a cell-based assay using several
laboratory-adapted and primary isolates in MT-2 cells
and PBMC, respectively. The inhibition of p24 produc-
tion in MT-2 cells was measured over a range of con-
centrations and the concentration required to inhibit
50% (IC50) of the p24 production was calculated. The
results in Table 2 indicate that NYAD-201 and its ana-
logs efficiently inhibited a broad range of HIV-1 strains,
representing different subtypes, which use R5, X4 or
R5X4 coreceptors including one X4-tropic RT-inhibitor-
resistant (AZT-R) strain ando n eX 4 - t r o p i cP R - i n h i b i -
tor-resistant strain. The stapled peptides inhibited the
laboratory strains with low μMp o t e n c y( I C 50 ~3 - 6
μM), and both R5- and X4-tropic viruses were inhibited
with similar potency. We also tested the linear peptide
and two control hydrocarbon-stapled peptides, NYAD-
215 and NYAD-233. Neither of these peptides showed
any antiviral activity even at a 100 μΜ dose (data not
shown).
Table 2 Antiviral activity (IC50) and cytotoxicity (CC50) of NYAD-201, NYAD-202 and NYAD-203 in laboratory-adapted
and primary HIV-1 isolates
HIV-1 virus Subtype Cell Type Coreceptor IC50 (μM±SD)
NYAD-201 NYAD-202 NYAD-203
Laboratory Strains IIIB B MT-2 X4 4.29 ± 0.62 2.36 ± 0.33 6.29 ± 0.54
MN B MT-2 X4 3.03 ± 0.61 2.47 ± 0.71
SF2 B MT-2 R5X4 5.06 ± 1.37 4.48 ± 0.84
RF B MT-2 X4 2.84 ± 0.63 2.64 ± 0.39
BaL B PBMC R5 4.73 ± 1.92 2.23 ± 0.44
89.6 B PBMC R5X4 5.21 ± 0.87 3.47 ± 0.22
RT-Resistant Isolate AZT-R B MT-2 X4 8.0 ± 1.27 4.53 ± 1.19 11.1 ± 3.82
PR-Resistant Isolate HIV-1RF/L-323-12-3 B MT-2 X4 5.6 ± 0.5 3.5 ± 0.6
Primary isolates 93RW024 A PBMC R5X4 9.88 ± 0.3 3.71 ± 0.19
92UG029 A PBMC X4 7.88 ± 1.01 3.97 ± 0.47
92US657 B PBMC R5 6.72 ± 0.98 3.61 ± 0.57
93IN101 C PBMC R5 1.58 ± 0.57 5.53 ± 0.39
98CN009 C PBMC R5 5.31 ± 0.83 4.08 ± 0.92
CMU02 EA PBMC X4 7.36 ± 0.69 4.2 ± 0.01
93BR020 F PBMC R5X4 2.78 ± 0.57 2.51 ± 0.43
RU570 G PBMC R5 7.48 ± 1.21 6.34 ± 2.22
BCF02 (Group 0) PBMC R5 15.84 ± 3.43 6.2 ± 1.2
Peptides CC50 (μM) in MT-2 CC50 (μM)in PBMC
NYAD-201 >115 >115
NYAD-202 30.2 ± 4.32 >116
NYAD-203 13.24 ± 0.5 15.96 ± 1.47
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analogs against a panel of primary HIV-1 isolates in
PBMC representing mostly group M (subtypes from A
to G) with diverse coreceptor usage. The peptides
showed inhibition against all primary isolates tested
including one from group O. These peptides showed
similar inhibitory activities against this diverse range of
primary isolates, except against group O strain, which
showed somewhat reduced inhibition, indicating its
effectiveness against a wide range of HIV-1 isolates.
The cytotoxicity of the stapled peptides was assessed
by the XTT method in both MT-2 cells and PBMC.
Cytotoxicity assays were performed in parallel with the
HIV-1 inhibition assays. The CC50 (concentration of
inhibitor required to produce 50% cytotoxicity) values of
NYAD-201 in MT-2 cells and PBMC were >115 μM.
NYAD-202 is more cytotoxic in MT-2 cells (30) than in
PBMC (>116 μM). However, NYAD-203 was cytotoxic,
as observed previously for NYAD-13 [59].
Discussion
In this study, we describe the rational design of peptide-
based inhibitors derived from the HIV-1 CA dimeriza-
tion domain. This approach is based on the hypothesis
that these peptides will act as decoys and bind to the
monomeric CA, thereby preventing CTD dimer forma-
tion, a critical step in virus assembly and maturation.
We chose a fifteen residue linear segment from the
dimer interface (aa 178-192) to design the decoy based
on the HIV-1 CA dimer structure as well as the biophy-
sical studies of a dimer interface peptide, CAC1, which
was shown to form a heterocomplex with CA CTD with
an apparent dissociation constant of 50 μM [65]. How-
ever, it is well-known that peptides of such short length
tend to exist as random structures despite the fact that
the secondary and tertiary structures of this segment in
the CTD protein are a-helical. Since the a-helical struc-
ture is critical for dimer formation we used a hydrocar-
bon stapling technique [60,61,76,77] to stabilize the a-
helical structure of this short peptide. We selected resi-
dues 183 (i)a n d1 8 7( i+4)o ft h ea-helical segment for
stapling because they are centrally located opposite from
the dimer interface and expected not to interfere with
the binding of this modified stapled peptide to the CTD
monomer. We further modified other residues at the N-
and C-termini based on the thermodynamic dissection
analysis of the dimer interface [78] which showed that
mutation of certain residues enhanced the association
constant. It appears that the CTD dimer is required to
have weak association due to other critical functions
where monomers may play an important role; however,
to design effective inhibitors from the dimer interface
p e p t i d ew en e e dt or e d e s i g nt h es h o r tp e p t i d e sw i t h
enhanced binding affinity towards the CTD monomer.
Based on this requirement, we synthesized NYAD-201,
NYAD-202 and NYAD-203, a soluble analog of NYAD-
201. We also synthesized the linear analog of NYAD-
201 (NYAD-209) and a mutant analog of NYAD-201
(NYAD-233) after mutating two key dimer-interface
residues, W184A and M185A. CD analysis confirmed
that NYAD-201 and the mutant stapled peptide, NYAD-
233, had the characteristic helical spectrum, whereas the
linear analog, NYAD-209, showed no a-helicity. Since
assembly and formation of virus particles are intracellu-
lar events, these peptides must penetrate cells to exert
their action by preventing dimer formation and thereby
inhibiting particle production. Although the mechanism
of cell penetration is not clearly understood, these
stapled peptides penetrated cells as reported for similar
stapled peptides [60,61,79]. The modified peptides,
except the mutant peptide NYAD-233, inhibited particle
formation in vitro. These results support the structural
model that a relaxed dimer can produce immature parti-
cles; however, it is critical to achieve a compact CTD
configuration to form mature particles [80]. This finding
indicates that peptide-based inhibitors targeted to differ-
ent sites on the CTD, as described in this study as well
as in our earlier report [59], may provide mechanistic
insights into the viral assembly and maturation process
and may help in elucidating the structural requirements
in forming immature and mature virus particles.
We observe that NYAD-201 has a modest effect on
HIV-1 particle production. The finding that this peptide
does not inhibit EIAV VLP production and that the
control peptide NYAD-233 has no effect on either HIV-
1 or EIAV particle production indicates that the effect is
specific to the HIV-1 CA-CTD dimer interface. How-
ever, at this time, the mechanism of action of NYAD-
201 with respect to VLP formation is not clear. The
reduction in particle production could be due to effects
on a variety of aspects of Gag function (e.g., Gag stabi-
lity, trafficking, etc.) rather than to impaired immature
assembly per se.
We utilized ITC and sedimentation equilibrium cen-
trifugation to measure the effect of these stapled pep-
tides on the dissociation of the CTD dimer. The
enhanced dissociation of the CTD dimer in the presence
of progressively increasing concentrations of stapled
peptide was an indirect measure of the inhibitory activ-
ity by ITC. Despite the fact that NYAD-203, the soluble
analog of NYAD-201, fit a dimer dissociation model, the
effect on dissociation was modest. These data are in
contrast to the potent inhibition by these peptides in
antiviral assays. Similar discrepancies have been noted
with CAP-1, a CA-NTD-targeted compound [81]. A
likely explanation for these results is that the local con-
centration of Gag is much higher (14 mM) [81] within
the densely packed lattice of the mature particle thus
Zhang et al. Retrovirology 2011, 8:28
http://www.retrovirology.com/content/8/1/28
Page 11 of 18ensuring that the bound peptide saturates a fraction of
the available sites. Hence, the relatively low affinity of
the peptide does not diminish its activity towards the
mature virus particle to the same extent that we observe
a limited effect on dissociation of the CTD in solution.
A characteristic feature of the CTD dimer interface in
solution is the overall flexibility of Helix II proposed to
facilitate rearrangement of the Gag molecules through
various stages of mature particle assembly [82]. Previous
studies have established that mutant CTD can exist as a
stable monomer and is remarkably similar to the subu-
nits of the native dimer structure [64]. The stability of
the monomer structure is then not tightly coupled with
dimerization and it can exist as an independent domain
without unfolding completely [83,84]. The monomeric
CTD mutant (W184A/M185A) has a hydrophobic
pocket on the distal side of the dimer interface known
to bind peptides [85] but in this instance has no mea-
surable affinity for NYAD-203 (data not shown). There-
fore we hypothesize that the stapled peptide NYAD-203,
a structural mimic of helix II, interacts with the transi-
ently exposed helix-II at the interface of the dimer by a
dynamic mechanism. The peptide is unlikely to favor a
single binding mode and the evidence for dynamic
exchange between conformational states is seen through
the excessive broadening and/or presence of multiple
complex peaks through the titration by NMR. Prelimin-
ary analysis of the NMR data suggests that the CTD
structure complexed with the peptide undergoes a con-
formational change in the core packing of hydrophobic
residues. Despite the modest peptide affinity, the partial
loss of the CTD dimer interface and subtle changes in
the monomer structure of the Gag molecules is
expected to disrupt and inhibit the assembly of the cap-
sid particle. Contrary to the biophysical and NMR evi-
dence in support of direct interactions between the
peptide and CTD, in vitro the homologous peptide
NYAD-201 appears to have no effect on the immature
particles but only disrupts the mature particles. A possi-
ble explanation for this observation can be traced to the
closely-packed lattice of cup shaped NTD hexamers in
the immature virus particle stabilized from the bottom
by SP1 interactions reinforced by inter- and intra-hex-
amer CTD contacts [80,86]. Following the proteolysis of
the CTD-SP1 junction the fullerene-like structure of the
capsid is assembled from NTD hexamers augmented by
CTD dimerization across NTD rings [5]. In the mature
particle the spacing of the CTD domains in each CA
hexamer is increased and the concomitant dimer con-
tacts are only possible between two capsids. We specu-
late that this reorganization of the subunits of CA is an
important structural determinant that facilitates greater
access of CTD to the peptide inhibitor in the lattice of
the mature particle thus increasing its effectiveness.
Unfortunately the current resolution of the recon-
structed CTD models lacks the atomic detail necessary
to make definitive comparisons between the dynamics
and buried surface triggered by the viral capsid assembly
mechanism.
These peptides showed potential as antivirals against
several laboratory-adapted and primary HIV-1 isolates,
including one RT-inhibitor-resistant and one PR-inhibi-
tor-resistant strain. NYAD-201 and NYAD-202 showed
encouragingly broad-spectrum activity, irrespective of
the subtype, coreceptor use and drug-resistance status
of the isolates. However, NYAD-203 was cytotoxic, as
was NYAD-13 [59], a similarly prepared soluble analog
of NYAD-1. Despite the fact that we have yet to confirm
the mechanism of action of these peptides, we have
demonstrated specificity by using a peptide (NYAD-233)
mutated in the two critical amino acids (W184 and
M185) at the dimer interface. This control dimer-inter-
face-disrupted peptide showed a loss of activity in virus
particle production and infectivity assays.
Conclusions
In conclusion, these preliminary data serve as the foun-
dation for designing small, stable, a-helical peptides and
small-molecule inhibitors targeted to the CTD dimer
interface. The observation that relatively weak CA bin-
d e r s ,s u c ha sN Y A D - 2 0 1a n dN Y A D - 2 0 2 ,a r es u f f i c i e n t
to dissociate and deform the virion cores offers encour-
agement for the exploration of a much broader class of
antiviral compounds targeting CA. We cannot exclude
the possibility that the CA-based peptides described
here could elicit additional effects on virus replication
not directly linked to their ability to bind the CA-CTD.
For example, the observation that under some circum-
stances the effect of NYAD-201 on virus infectivity
could be mitigated by VSV-G pseudotyping suggests
that this peptide may also impose an entry-related
defect; however, these peptides failed to inhibit virion
uptake. Furthermore, there is precedent for CA-related
defects being reversible by VSV-G pseudotyping. Brun
et al. [75] reported that a mutation in the linker domain
between CA-NTD and CA-CTD disrupts core stability.
This core disruption imposed an infectivity defect that
was reversed in virions bearing VSV-G, instead of HIV-
1 Env [75]. Similarly, a mutation in the CA NTD
(N74D) has been shown to bypass the need for the
nuclear import factor transportin-SR2 in HIV-1 infec-
tion [87]; however, the transportin-SR2 independence
conferred by the N74D mutation was Env glycoprotein
dependent in that VSV-G-pseudotyped N74D virus
could infect cells depleted of transportin-SR2 but N74D
virus bearing HIV-1 Env could not [88]. These observa-
tions may be attributable to differences in the uncoating
process associated with different routes of viral entry
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inhibitory peptides reported here could disrupt CA
post-entry function in a manner reversible by a VSV-G-
mediated entry route. Further studies will be required to
more fully understand the role that CA plays in early
post-entry events and to more precisely define the step
at which inhibitory peptides like NYAD-201 act.
Methods
Reagents
AZT (Cat# 3485), T-20, [fusion inhibitor from Roche
(Cat# 9845)], MT-2 cells (Dr. D. Richman), Sup-T1 cells
(Dr. James Hoxie), laboratory adapted and primary HIV-
1 strains, U87-T4-CXCR4 cells were obtained through
the NIH AIDS Research and Reference Reagent Pro-
gram. 293T cells were obtained from the American
Type Culture Collection. PBMC were processed from
blood obtained from the New York Blood Center.
Molecular cloning, protein expression and purification
pET14b or pET28a plasmids encode Gag-derived pro-
teins from the HIV-1NL4-3 strain. The full-length gag
expression vector was obtained from the NIH AIDS
Research and Reference Reagent Program. The CA cod-
ing region was obtained by PCR amplification and was
inserted into the pET28a vector. The C-CA DNA frag-
ment was provided by Drs Ming Luo and Peter E Preve-
lige Jr. The C-CA DNA fragment was subcloned into
the pET14b vector. The C-CA mutant (W184A/M185A)
was generated from pET14b-C-CA by overlapping PCR.
The corresponding proteins (including
15No r
15N/
13C
labeled mutant C-CA and C-CA) were expressed and
purified as described previously
10, 47, 53. Protein concen-
trations were determined with the A280 molar extinction
coefficients of 2.980 M
-1cm
-1(C-CA, mutant), 8,480 M
-
1cm
-1(C-CA), 33,460 M
-1cm
-1(CA) and 64,400 M
-1cm
-1
(Gag), respectively.
Virus assembly and release assays and
immunoprecipitation analysis
For metabolic radiolabeling assays, 293T cells (plated
at 2.5 × 10
5 cells/well in 12-well dishes) were trans-
fected with the HIV-1 molecular clone pNL4-3 [89],
the EIAV Gag expression construct pPRE-Gag [90,91],
or the HIV-1 Gag expression vector pCMVdeltaR8.2/
PR-. This clone was constructed from pCMVdelR8.2
[92] by introducing the PR-inactivating mutation from
pNL4-3/PR- [93]. Five h posttransfection, cells were
treated with the indicated concentrations of NYAD-
201 or control peptide NYAD-233 for 16-20 h. One
day posttransfection, cells were metabolically labeled
for 2 h (HIV-1) or 5 h (EIAV) with 250 μCi [
35S]Met/
Cys. The labeled virions were pelleted in an ultracentri-
fuge and cell and virus lysates were immunoprecipitated
and subjected to SDS-PAGE. Quantification was per-
formed by Phosphorimager analysis, and virus release
efficiency was calculated as the amount of virion-asso-
ciated Gag as a fraction of total (cell- plus virion-asso-
ciated) Gag synthesized during the metabolic labeling
period. HIV-1 immunoglobulin (HIV-Ig) antiserum was
obtained from the NIH AIDS Research and Reference
Reagent Program. EIAV horse serum was kindly pro-
vided by Dr. Ronald Montelaro (University of
Pittsburgh).
Synthesis of stapled peptides
The peptides were synthesized manually by Fmoc solid
phase synthesis as described previously [59].
CD spectroscopy
CD spectra were obtained on a Jasco J-715 Spectropo-
larimeter (Jasco Inc, Japan)a t2 0 ° Cu s i n gt h es t a n d a r d
measurement parameters in Tris-HCl buffer (20 mM
Tris, pH 8.0) in the presence of 1-15% (vol/vol) acetoni-
trile at a final concentration of 125-500 μM. In all the
samples, the final concentrations of peptides and salt
were always the same, and the spectra were corrected
by subtracting the CD spectra of the appropriate refer-
ence solvent.
Confocal microscopy
For the cell penetration study, 293T cells were seeded in
4-well chamber plates and incubated at 37°C with 5 μΜ
of FITC-conjugated peptides in serum-free medium for
4 h and/or an additional 16 h in medium containing
serum. After three washes with 1× PBS, live cells were
examined and imaged under a Zeiss LSM510 laser scan-
ning confocal microscope (Zeiss).
Electron microscopy to study inhibition of in vitro
assembly by peptides
In vitro assembly systems were set up as described
[15,68,94,95] with minor modification. We used 50
mM Na2HPO4,p H8 . 0a st h ed i a l y s i sb u f f e r .T h eb u f -
fer used for assembly studies also contained 0.1~2 M
of NaCl. 500-Da-MWCO dialysis tubes (Spectra/Por)
were used for the dialysis of peptides. Briefly, stock
proteins were adjusted to the appropriate concentra-
tion (25 μΜ for Gag proteins or 50 μΜ for CA pro-
teins) with the Na2HPO4 buffer at pH 8.0. After
addition of 5% total E. coli RNA (RNA:protein = 1:20
by weight), incubation with varied doses of NYAD-201
a n dN Y A D - 2 3 3f o r3 0m i na t4 ° C ,t h es a m p l e sw e r e
dialyzed overnight in Na2HPO4 buffer at pH 8.0 con-
taining 100 mM NaCl at 4°C. For assembly of CA
mature-like particles, addition of 5% total E. coli RNA
was omitted. Negative staining was used to check the
assembly. Carbon-coated copper grids (200 mesh size;
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(1 mg/ml; Sigma) for 2 min. 20 μl of reaction solution
was placed onto the grid for 2 min. Spotted grids were
then stained with 30 μl of uranyl acetate solution for 2
min. Excess stain was removed, and grids were air-
dried. Specimens were examined with a TECNAI G
2
electron microscope.
ITC Analysis
The influence of the peptides on dimer dissociation of
wild type CTD (wtCTD) was investigated by ITC
(MicroCal VP-ITC) following established protocols
[96,97]. Proteins were exhaustively dialyzed against the
25 mM sodium phosphate buffer (pH 7.3) prior to
experimental measurements. In a typical experiment, the
ITC injection syringe was loaded with 250 μMp r o t e i n ,
dissolved in dialysis buffer or dialysis buffer/peptide
mixture and the calorimetric cell (ca. 1.4 ml active
volume) initially contained only the identical buffer mix-
ture. Typically titrations consisted of 28 injections of 10
μl, with 240-s equilibration between injections. The
thermodynamic parameters were obtained and data
were analyzed using MicroCal Origin 7.0 software, using
an updated and corrected (June 2008) version of the dis-
sociation analysis procedure, validated by comparison
with earlier analysis methods [96,97].
Sedimentation Velocity Centrifugation
Sedimentation velocity experiments were performed
using a ProteomeLab XL-A analytical ultracentrifuge
(Beckman Coulter) with 2-channel centerpieces in an
An-60Ti rotor at 42,000 rpm and 25°C. Radial scans at a
single wavelength (typically 280 nm) were taken at 300 s
intervals. The solvent density and viscosity and the pro-
tein partial specific volume were calculated using the
program SEDNTERP. Protein samples were dialyzed
into a buffer containing 50 mM sodium phosphate buf-
fer (pH 7.3). The data were fitted to the continuous
size-distribution functions g(S)u s i n gt h ep r o g r a m
SEDFIT.
Sedimentation Equilibrium Centrifugation
Sedimentation equilibrium experiments were performed
using a ProteomeLab XL-A analytical ultracentrifuge
using 6-channel centerpieces in an An-60Ti rotor at 25°
C. Protein samples were dialyzed into 50 mM sodium
phosphate buffer (pH 7.3). Samples were centrifuged for
~16 h at 28000 rpm, 32000 rpm or 36000 rpm until
they reached equilibrium and no further change was
seen in the distribution. Radial scans were measured at
280 nm. The data were fitted to an ideal single-species
model as well as a rapid monomer-dimer equilibrium
using the Beckman XL-A/XL-I Data Analysis Software
(Version 6.03).
NMR Experiments
Standard
1H-
13C HSQC spectra were acquired on a 7
μMs a m p l eo f[ U -
13C,
15N] CTD complexed with
NYAD-203 at various concentrations ranging from 0-
500 μM prepared in 20 mM phosphate buffer (90%
H2O/10% D2O) at pH 6.5. The protein concentration
was constant in every sample. The titration was followed
at 25°C by acquiring data on a 900 MHz AVANCE II
spectrometer equipped with TCI CryoProbe using 128
transients for signal averaging. The NMR data were pro-
cessed and analyzed in Topspin 2.1.
Preparation of GFP-Vpr-labeled HIV-1 virions
Green fluorescent protein (GFP)-expressing virions were
produced by cotransfection of 293T cells (plated in a
T75 flask) with HIV-1 pNL4-3 proviral DNA (15 μg)
and an expression vector (15 μg) encoding a GFP-Vpr
fusion protein. After 48 h, the virus-containing superna-
tant was subjected first to low-speed centrifugation to
remove cells and debris and then to ultracentrifugation
at 20,000 rpm in an SW41 rotor for 2 h at 4°C to sedi-
ment viral particles. The virus-containing pellet was
resuspended in complete medium (0.5 ml) and stored in
aliquots at -70°C. Twenty thousand SupT1 cells were
incubated with ~0.3 μg of p24-normalized virus particles
in the absence or presence of different dosages of
NYAD-201 and T-20 for 3 hours. After a treatment
with 1× Trypsin-EDTA (GIBCO) and one wash with 1×
PBS, the cells were fixed and subjected to FACS analysis
after another washing with 1× PBS.
Single-cycle infectivity assay
The single-cycle infectivity assays were performed by
using the TZM-bl indicator cell line (obtained from
John Kappes through the NIAID AIDS Reagent Pro-
gram), which contains integrated copies of the b-galac-
tosidase and luciferase genes under control of the HIV-1
LTR [73,98]. One day before infection, TZM-bl cells (4
×1 0
4 cells/well) were seeded in a 24-well tissue culture
plate. RT-normalized (200,000 RT cpm) virus stocks
were used to infect the TZM-bl cells. NYAD-201 was
added to cells before or after infection or was present
during the 2 h infection period as indicated. To generate
VSV-G-pseudotyped viruses, 293T cells were cotrans-
fected with the Env-defective pNL4-3 derivative (pNL4-
3/KFS) [99] and the VSV-G expression vector pHCMV-
G [100]. After 48 h, cells were washed with PBS and
lysed in luciferase lysis buffer (Promega) and infection
efficiency was determined by measuring luciferase activ-
ity. The samples were assayed with the Promega lucifer-
ase assay substrate (Promega) in a multifunctional
microplate reader.
For experiments in which the producer cells were
treated with NYAD-201 for 2 or 4 days, 293T cells were
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cells were washed and medium containing the indicated
concentrations of NYAD-201 was added. Virus superna-
tant was collected 2 or 4 days posttransfection and RT-
normalized virus was used for infectivity assays.
In vitro experiments were performed as follows: 293T
cells in 60-mm dishes were transfected as above and the
virus supernatant was collected 24 h posttransfection.
Virus supernatants from several 60-mm dishes were
pooled and aliquoted into several tubes. NYAD-201 was
added to the virus supernatants at indicated concentra-
tions and incubated for approximately 20 h at 37°C. A
small aliquot of virus supernatant was stored for infec-
tivity assays.
Measurement of multi-round HIV-1 replication
The inhibitory activity of NYAD-201 and other stapled
peptides on replication by laboratory-adapted HIV-1
strains was determined as previously described [101]
with minor modification. In brief, 1 × 10
4 MT-2 cells
were infected with HIV-1 at 100 TCID50 (50% tissue
culture infective dose) (0.01MOI) in 200 μl RPMI 1640
medium containing 10% FBS in the presence or absence
of peptides at graded concentrations overnight. The cul-
ture supernatants were then removed and fresh media
containing freshly prepared test peptide were added. On
the fourth day post-infection, 100 μl of culture superna-
tants were collected from each well, mixed with equal
volume of 5% Triton X-100 and tested for p24 antigen
by ELISA.
The inhibitory activity of peptides on replication by
primary HIV-1 isolates was determined as previously
described [102]. PBMCs were isolated from the blood of
healthy donors at the New York Blood Center by stan-
dard density gradient centrifugation using Histopaque-
1077 (Sigma-Aldrich). The cells were cultured at 37°;C
for 2 h. Nonadherent cells were collected and resus-
pended at 5 × 10
6 cells/ml RPMI-1640 medium contain-
ing 10% FBS, 5 μg/ml PHA, and 100 U/ml IL-2 (Sigma-
Aldrich), followed by incubation at 37°;C for 3 days. The
PHA-stimulated cells (5 × 10
4 cells/ml) were infected
with primary HIV-1 isolates at 500 TCID50 (0.01 MOI)
in the absence or presence of peptide inhibitor at graded
concentrations. Culture media were changed every 3
days and replaced with fresh media containing freshly
prepared inhibitor. The supernatants were collected 7
days post-infection and tested for p24 antigen by ELISA.
The percent inhibition of p24 production, IC50 and IC90
values were calculated by the GraphPad Prism software
(GraphPad Software Inc.).
Cytotoxicity assay
Cytotoxicity of peptides in MT-2 cells and PBMC was
measured by the XTT [(sodium 3’-(1-(phenylamino)-
carbonyl)-3,4-tetrazolium-bis(4-methoxy-6-nitro) beze-
nesulfonic acid hydrate)] method as previously described
[102]. Briefly, for MT-2 cells, 100 μl of a peptide at
graded concentrations was added to an equal volume of
cells (1 × 10
5 cells/ml) in 96-well plates followed by
incubation at 37°C for 4 days, which ran parallel to the
neutralization assay in MT-2 (except medium was added
instead of virus). In the case of PBMC, 5 × 10
5 cells/ml
were used and the cytotoxicity was measured after 7
d a y s .A f t e ra d d i t i o no fX T T( P o l y S c i e n c e s ,I n c . ) ,t h e
soluble intracellular formazan was quantitated colorime-
trically at 450 nm 4 h later with a reference at 620 nm.
T h ep e r c e n to fc y t o t o x i c i t ya n dt h eC C 50 values were
calculated as above.
Additional material
Additional file 1: Fig-S1. Cell penetration of NYAD-233 and its linear
analog NYAD-209 in 293T cells. Confocal microscopy images of 293T
cells incubated for 20 hours at 37°C with FITC-conjugated peptides.
Upper panel: Left, Differential Interference Contrast (DIC) image of cells
with FITC-b-Ala-NYAD-209; Center, FITC fluorescent image of the same
cells with FITC-b-Ala-NYAD-209; and Right, Overlay of DIC and FITC
fluorescent images. Lower panel: Left, DIC image of cells with FITC-b-Ala-
NYAD-233; Center, FITC fluorescent image of the same cells with FITC-b-
Ala-NYAD-233; and Right, Overlay of DIC and FITC fluorescent images. A
total of 200 cells were scored in each treatment with FITC-b-Ala-NYAD-
209 or FITC-b-Ala-NYAD-233. The percentage of cells in the population
that exhibited the internal staining is shown at the bottom right of the
middle panel.
Additional file 2: Fig-S2. The
1H-
13C HSQC spectra of CTD
complexed with the peptide NYAD-203. The three panels display the
effect of the titration on select crosspeaks from the aliphatic region
through the titration. Resonances from the protein that could be
assigned unambiguously are annotated in black and those from the
excess peptide are indicated in blue. (A) The population weighted
changes in the Lys199 Ca cross-peak intensity in the free and bound
states at four peptide concentrations. (B) and (C) The effect of peptide
addition on W184 Ca and Cδ1 cross-peak. (D) Standard one dimension
proton NMR spectra of NYAD-203 at various concentrations in 20 mM
phosphate buffer at pH 7.0 and 288 K. The NMR data were processed
and analyzed in Topspin 2.1.
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